KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Net Cash Flow: 2016-2024

Historic Net Cash Flow for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to -$999.0 million.

  • Moderna's Net Cash Flow rose 82.25% to -$148.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$514.0 million, marking a year-over-year increase of 60.67%. This contributed to the annual value of -$999.0 million for FY2024, which is 245.67% down from last year.
  • As of FY2024, Moderna's Net Cash Flow stood at -$999.0 million, which was down 245.67% from -$289.0 million recorded in FY2023.
  • Moderna's Net Cash Flow's 5-year high stood at $4.2 billion during FY2021, with a 5-year trough of -$3.6 billion in FY2022.
  • Moreover, its 3-year median value for Net Cash Flow was -$999.0 million (2024), whereas its average is -$1.6 billion.
  • Its Net Cash Flow has fluctuated over the past 5 years, first spiked by 665.88% in 2020, then crashed by 245.67% in 2024.
  • Moderna's Net Cash Flow (Yearly) stood at $2.4 billion in 2020, then spiked by 76.88% to $4.2 billion in 2021, then tumbled by 186.25% to -$3.6 billion in 2022, then soared by 92.07% to -$289.0 million in 2023, then tumbled by 245.67% to -$999.0 million in 2024.